fda warning compounding semaglutide october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Semaglutide Patient Safety Updates |

The benefit for Mochi using an array of pharmacies to send prescriptions through is: if one pharmacy runs into an issue due to inventory shortages )or some form of regulatory issue), then Mochi can continue to provide the medication to the patient without interruption

Clean and conservative Below 12 mg/mL, the 12 mg dose volume exceeds 1 mL, requiring either a tuberculin syringe or splitting the injection

The speed and extent of results depend on several factors, including starting BMI, metabolic health, adherence to the prescribed dose titration schedule, diet quality, and physical activity levels

Part of it is due to the rapid weight loss and part of it is possibly a lack of proper nutrition in patients taking these medications, says John Diaz, MD, a plastic surgeon in Beverly Hills, CA

Such changes should not automatically cause worry

tirzepatide vs